Drugs & Aging

, Volume 2, Issue 3, pp 208–221 | Cite as

Ocular β-Blockers in Glaucoma Management

Clinical Pharmacological Aspects
  • Anne M. V. Brooks
  • W. E. Gillies
Review Article Clinical Pharmacology

Summary

Topical β-blockers reduce the intraocular pressure (IOP) by blockade of sympathetic nerve endings in the ciliary epithelium causing a fall in aqueous humour production. Two types of topical β-blockers are available for use in glaucoma: nonselective, which block both β1- and β2-adrenoceptors; and cardioselective, which block only β1-receptors.

Of the β-Blockers commercially available, timolol, levobunolol, metipranolol and Carteolol are nonselective, and betaxolol is cardioselective. Twice-daily timolol is probably the most effective agent in lowering IOP, although levobunolol is equally effective and can be used once daily with little difference in effect. Carteolol is used twice daily and any theoretical advantage in diminished side effects confered by its partial β-agonist activity compared with timolol has not been fully substantiated. Metipranolol is effective twice daily and does not have partial β-agonist activity. Betaxolol has an effect comparable to timolol in lowering IOP, but is less effective in some patients.

β-Blockers can be used with other antiglaucoma medications, but their combined action with epinephrine (adrenaline) is suspect, particularly in the case of the nonselective β-blockers, and the effect should be assessed in patients on an individual basis. Local stinging can be a problem in some patients with betaxolol. The most serious side effects of β-blockers are the exacerbation of chronic obstructive airways disease with nonselective agents and the precipitation of bron-chospasm in some patients. Betaxolol seems relatively free of adverse respiratory effects, although this may be dose-related and extreme caution should still be exercised in patients with any history of respiratory illness. Because of the lower risk of precipitating side effects, betaxolol is probably the β-blocker of first choice for use in glaucoma; timolol or levobunolol are reserved for patients who do not respond satisfactorily to betaxolol and are quite free of respiratory disease.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Airaksinen PJ. The long-term hypotensive effect of timolol maleate compared with the effect of pilocarpine in simple and capsular glaucoma. Acta Ophthalmologica 57: 425–434, 1979PubMedGoogle Scholar
  2. Airaksinen PJ, Valkonen R, Stenborg T, Takki K, Klemetti A, et al. A double-masked study of timolol and pilocarpine combined. American Journal of Ophthalmology 104: 587–594, 1987PubMedGoogle Scholar
  3. Akingbehin T, Villada JR. Metipronolol-associated granulomatous anterior uveitis. British Journal of Ophthalmology 75: 519–523, 1991PubMedGoogle Scholar
  4. Allen RC, Epstein DL. A double-masked clinical trial of betaxolol and timolol in glaucoma patients. Investigative Ophthalmology and Visual Science 23 (Suppl. 40): 1982Google Scholar
  5. Allen RC, Epstein DL. Additive effect of betaxolol and epinephrine in primary open angle glaucoma. Archives of Ophthalmology 104: 1178–1184, 1986PubMedGoogle Scholar
  6. Allen RC, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. American Journal of Ophthalmology 101: 535–541, 1986PubMedGoogle Scholar
  7. Allen RC, Robin AL, Long D, Novack GD, Lue JC, et al. A combination of levobunolol and dipivefrin for the treatment of glaucoma. Archives of Ophthalmology 106: 904–907, 1988PubMedGoogle Scholar
  8. Anderson DR. Glaucoma: the damage caused by pressure. XLVI Edward Jackson Memorial Lecture. American Journal of Ophthalmology 108: 485–495, 1989PubMedGoogle Scholar
  9. Andréasson S, Jensen KM. Effect of pindolol on intraocular pressure in glaucoma: pilot study and randomised comparison with timolol. British Journal of Ophthalmology 67: 228–230, 1983PubMedGoogle Scholar
  10. Ashburn FS, Gillespie JE, Kass MA, Becker B. Timolol plus maximum tolerated antiglaucoma therapy: a one-year followup study. Survey of Ophthalmology 23: 389–394, 1979PubMedGoogle Scholar
  11. Atkins JM, Pugh BR, Timewell RM. Cardiovascular effects of topical beta-blockers during exercise. American Journal of Ophthalmology 99: 173–175, 1985PubMedGoogle Scholar
  12. Ball S. Congestive heart failure from betaxolol. Archives of Ophthalmology 105: 320, 1987PubMedGoogle Scholar
  13. Battershill PE, Sorkin EM. Ocular metipranolol. Drugs 36: 601–615, 1988PubMedGoogle Scholar
  14. Beasley CH, Cagle GD, McDonald TO. Long-term efficacy and safety of betaxolol 0.5% ophthalmic solution. New Trends in Ophthalmology 2: 95–97, 1987Google Scholar
  15. Bengtsson B. Aspects of the epidemiology of chronic glaucoma. Acta Ophthalmologica Supplementum 146: 1–48, 1981PubMedGoogle Scholar
  16. Bensinger RE, Keates EU, Gofman JD, Novack GD, Duzman E. Levobunolol: a three-month efficacy study in the treatment of glaucoma and ocular hypertension. Archives of Ophthalmology 103: 375–378, 1985PubMedGoogle Scholar
  17. Berger WE. Betaxolol in patients with glaucoma and asthma. American Journal of Ophthalmology 103: 600–601, 1987PubMedGoogle Scholar
  18. Berlin I, Marcel P, Uzzan B, Millon D, Le Hoang P, et al. A single dose of three different ophthalmic beta-blockers antagonizes the chronotropic effect of isoproterenol in healthy volunteers. Clinical Pharmacology and Therapeutics 41: 622–626, 1987PubMedGoogle Scholar
  19. Berrospi AR, Leibowitz HM. A new β-adrenergic blocking agent for treatment of glaucoma. Archives of Ophthalmology 100: 943–946, 1982PubMedGoogle Scholar
  20. Berry DP, Van Buskirk EM, Shields MB. Betaxolol and timolol: a comparison of efficacy and side effects. Archives of Ophthalmology 102: 42–45, 1984PubMedGoogle Scholar
  21. Berson FG, Cohen HB, Foerster RJ, Lass JH, Novack GD, et al. Levobunolol compared with timolol for the long-term control of elevated intraocular pressure. Archives of Ophthalmology 103: 379–382, 1985PubMedGoogle Scholar
  22. Björnsson G. The primary glaucoma in Iceland. Acta Ophthalmologica Supplementum 91: 1–99, 1967Google Scholar
  23. Bleckmann H, Dorow P. Betaxolol vs placebo in ten patients with glaucoma and reactive airway disease. New Trends in Ophthalmology 2: 114–123, 1987Google Scholar
  24. Bloom E, Richmond C, Alvarado J, Polansky J. Betaxolol vs timolol: plasma radio-receptor assays to evaluate systemic complications of beta blocker therapy for glaucoma. Investigative Ophthalmology and Visual Science 26 (Suppl.): 125, 1985Google Scholar
  25. Boger WP, Puliafito CA, Steinert RF, Langston DP. Long-term experience with timolol ophthalmic solution in patients with open-angle glaucoma. Ophthalmology 85: 259–267, 1978PubMedGoogle Scholar
  26. Boger WP, Steinert RF, Thomas JV. Timolol in the therapy of ‘Ocular Hypertension’. Survey of Ophthalmology 25: 195–202, 1980PubMedGoogle Scholar
  27. Bonomi L, Steindler P. Effect of pindolol on intraocular pressure. British Journal of Ophthalmology 59: 301–303, 1975PubMedGoogle Scholar
  28. Bonomi L, Zavarise G, Noya E, Michieletto S. Effects of timolol maleate on tear flow in human eyes. Albrecht Von Grafes Archiv fur Klinische und Experimentelle Ophthalmologie 213: 19–22, 1980Google Scholar
  29. Boozman FW, Carriker R, Foerster R, Allen RC, Novack GD, et al. Long-term evaluation of 0.25% levobunolol and timolol for therapy for elevated intraocular pressure. Archives of Ophthalmology 106: 614–618, 1988PubMedGoogle Scholar
  30. Boudot JP, Cavero I, Fénard S, Lefèvre-Borg F, Manoury P, et al. Preliminary studies on SL 75212, a new potent cardioselective β-adrenoceptor antagonist. British Journal of Pharmacology (Proceedings) 66: 445P, 1979Google Scholar
  31. Brazier DJ, Smith SE. Ocular and cardiovascular response to topical Carteolol 2% and timolol 0.5% in healthy volunteers. British Journal of Ophthalmology 72: 101–103, 1988PubMedGoogle Scholar
  32. Brenkman RF. Long-term hypotensive effect of atenolol 4% eye drops. British Journal of Ophthalmology 62: 287–291, 1978PubMedGoogle Scholar
  33. Brogliatti B, Rolle T, Franzone M. Effects of topical betaxolol on ocular hypertensive or glaucomatous eyes. New Trends in Ophthalmology 2: 87–94, 1987Google Scholar
  34. Brooks AMV, Burdon JGW, Gillies WE. The significance of reactions to betaxolol reported by patients. Australian and New Zealand Journal of Ophthalmology 17: 353–355, 1989PubMedGoogle Scholar
  35. Brooks AMV, Gillies WE, West RH. Betaxolol eye drops as a safe medication to lower intraocular pressure. Australian and New Zealand Journal of Ophthalmology 15: 125–129, 1987PubMedGoogle Scholar
  36. Buckley MM-T, Goa KL, Clissold SP. Ocular betaxolol. A review of its pharmacological properties, and therapeutic efficacy in glaucoma and ocular hypertension. Drugs 40: 75–90, 1990PubMedGoogle Scholar
  37. Caldwell DR, Salisbury CR, Guzek JP. Effects of topical betaxolol in ocular hypertensive patients. Archives of Ophthalmology 102: 539–540, 1984PubMedGoogle Scholar
  38. Cavero I, Lefèvre-Borg F. Antihypertensive activity of betaxolol in conscious spontaneously hypertensive rats. British Journal of Pharmacology 78 (Proceedings): 141P, 1983Google Scholar
  39. Cervantes R, Hernandez y Hernandez H, Frati A. Pulmonary and heart rate changes associated with nonselective beta-blocker glaucoma therapy. Journal of Toxicology — Cutaneous and Ocular Toxicology 5: 185–193, 1986Google Scholar
  40. Cher I. Transfer to timolol: selective use of a new mode of therapy. Australian Journal of Ophthalmology 8: 165–172, 1980PubMedGoogle Scholar
  41. Chrisp P, Sorkin EM. Ocular Carteolol. A review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs & Aging 2: 58–77, 1992Google Scholar
  42. Cinotti A, Cinotti D, Grant W, Jacobs I, Galin M, et al. Levobunolol vs timolol for open-angle glaucoma and ocular hypertension. American Journal of Ophthalmology 99: 11–17, 1985PubMedGoogle Scholar
  43. Clark JB, Brooks AMV, Mantzioros N, Gillies WE. A comparison of the efficacy of betaxolol and timolol in ocular hypertension with or without adrenaline. Australian and New Zealand Journal of Ophthalmology 17: 173–177, 1989PubMedGoogle Scholar
  44. Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. Archives of Ophthalmology 96: 2045–2048, 1978PubMedGoogle Scholar
  45. Cohn JB. A comparative study of the central nervous system effects of betaxolol vs timolol. Correspondence. Archives of Ophthalmology 107: 633–634, 1989Google Scholar
  46. Collignon-Brach J. Early visual field changes with beta-blocking agents. Summary. Survey of Ophthalmology 33 (Suppl.): 429–430, 1989PubMedGoogle Scholar
  47. Cyrlin MN, Thomas JV, Epstein DL. Additive effect of epinephrine to timolol therapy in primary open angle glaucoma. Archives of Ophthalmology 100: 414–418, 1982PubMedGoogle Scholar
  48. David R, Sachs U. Timolol: long-term follow-up of patients with various types of glaucoma and ocular hypertension. Glaucoma 3: 323–325, 1981Google Scholar
  49. DeSantis L, Chandler M. Cardiac beta blockade after ocular instillation of beta adrenergic blockers in alert cynomolgus monkeys: safety profile for betaxolol. Investigative Ophthalmology and Visual Science 26: 227, 1985Google Scholar
  50. DeSantis L, Polansky JR, Bruce L. Relative differences in beta receptor activity between the cardioselective beta blocker, betaxolol, and nonselective beta blockers. In Blodi F, et al. (Eds) Proceedings of the XXVth International Congress of Ophthalmology, pp. 1501–1505, Kugler & Ghedini, Amsterdam, 1987Google Scholar
  51. Dickstein K. Comparison of the effect of timolol versus betaxolol Ophthalmic on cardiopulmonary exercise performance in healthy volunteers. Survey of Ophthalmology 33 (Suppl.): 457–458, 1989PubMedGoogle Scholar
  52. Duff GR, Graham PA. A double-crossover trial comparing the effects of topical Carteolol and placebo on intraocular pressure. British Journal of Ophthalmology 72: 27–28, 1988PubMedGoogle Scholar
  53. Duff GR, Newcombe RG. The 12-hour control of intraocular pressure on Carteolol 2% twice daily. British Journal of Ophthalmology 72: 890–891, 1988PubMedGoogle Scholar
  54. Dunn TL, Gerber MJ, Shen AS, Fernandez E, Iseman MD, et al. The effect of topical ophthalmic instillation of timolol and be-taxolol on lung function in asthmatic subjects. American Review of Respiratory Disease 133: 264–268, 1986PubMedGoogle Scholar
  55. Duzman E, Ober M, Scharrer A, Leopold IH. A clinical evaluation of the effects of topically applied levobunolol and timolol on increased intraocular pressure. American Journal of Ophthalmology 94: 318–327, 1982PubMedGoogle Scholar
  56. Elliot MJ, Cullen PM, Phillips CI. Ocular hypotensive effect of atenolol (Tenormin, I.C.I.): a new beta-adrenergic blocker. British Journal of Ophthalmology 59: 296–300, 1975PubMedGoogle Scholar
  57. Epstein DL, Krug JH, Hertzmark E, Remis LL, Edelstein DJ. A long-term clinical trial of timolol therapy versus no treatment in the management of glaucoma suspects. Ophthalmology 96: 1460–1467, 1989PubMedGoogle Scholar
  58. Feghali JG, Kaufman PL. Decreased intraocular pressure in the hypertensive human eye with betaxolol, a β1-adrenergic antagonist. American Journal of Ophthalmology 100: 777–782, 1985PubMedGoogle Scholar
  59. Fraunfelder FT, Barker AF. Respiratory effects of timolol. Correspondence. New England Journal of Medicine 311: 1441, 1984PubMedGoogle Scholar
  60. Frumar KD, McGuinness R. A study of the intraocular pressure lowering effect of timolol and dipivalyl epinephrine. Transactions of the Ophthalmological Society of New Zealand 33: 27–29, 1981PubMedGoogle Scholar
  61. Gerber SL, Cantor LB, Brater DC. Systemic drug interactions with topical glaucoma medications. Survey of Ophthalmology 35: 205–218, 1990PubMedGoogle Scholar
  62. Gillies WE, West RH, Cebon L. A trial of timoptol (Timolol Maleate) in a clinical situation. Australian Journal of Ophthalmology 8: 173–175, 1980Google Scholar
  63. Gillies WE, West RH, Cebon L. Timoptol — three years on: a study of timolol maleate drops over a longer period. Australian Journal of Ophthalmology 11: 155–157, 1983PubMedGoogle Scholar
  64. Goldberg I. Betaxolol. Australian and New Zealand Journal of Ophthalmology 17: 9–13, 1989PubMedGoogle Scholar
  65. Gonzalez JP, Clissold SP. Ocular Levobunolol. A Review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 34: 648–661, 1987PubMedGoogle Scholar
  66. Graham PA. Prevalence of glaucoma: population surveys. Transactions of the ophthalmological societies of the United Kingdom 98: 288–289, 1978PubMedGoogle Scholar
  67. Grunwald JE. Effect of timolol maleate on the retinal circulation of human eyes with ocular hypertension. Investigative Ophthalmology and Visual Science 31: 521–526, 1990PubMedGoogle Scholar
  68. Harris LS, Greenstein SH, Bloom AF. Respiratory difficulties with betaxolol. Correspondence. American Journal of Ophthalmology 102: 274–275, 1986PubMedGoogle Scholar
  69. Hernandez y Hernandez H, Cervantes R, Frati A, Hurtado R, et al. Cardiovascular effects of topical glaucoma therapies in normal subjects. Journal of Toxicology — Cutaneous and Ocular Toxicology 2: 99–106, 1983Google Scholar
  70. Hollows FC, Graham PA. Intra-ocular pressure, glaucoma, and glaucoma suspects in a defined population. British Journal of Ophthalmology 50: 570–586, 1966PubMedGoogle Scholar
  71. Holmin C, Krakau CET. Short term effects of timolol in chronic glaucoma: a double blind study using computerized perimetry. Acta Ophthalmologica 60: 337–346, 1982PubMedGoogle Scholar
  72. Hoskins HD, Kass MA (Eds) Becker-Shaffer’s diagnosis and therapy of the glaucomas, pp. 455, CV Mosby, St Louis, 1989Google Scholar
  73. Høvding G, Aasved H. Timolol/pilocarpine combination eye drops in open angle glaucoma and in ocular hypertension: a controlled randomized study. Acta Ophthalmologica 65: 594–601, 1987PubMedGoogle Scholar
  74. Huckauf H. Respiratory tolerance of oral betaxolol in partially reversible obstructive airways disease. In Morselli RL, et al. (Eds) Betaxolol and other β1-adrenoreceptor antagonists, pp. 205–211, Raven Press, New York, 1983Google Scholar
  75. Hugues FC, Julien D, Marche J. Influence of betaxolol and atenolol on airways in chronic obstructive lung diseases. In Morselli RL et al. (Eds) Betaxolol and other β1-adrenoreceptor antagonists, pp. 195–203, Raven Press, New York, 1983Google Scholar
  76. James IM. Pharmacologic effects of beta-blocking agents used in the management of glaucoma. Summary. Survey of Ophthalmology 33 (Suppl.): 453–454, 1989PubMedGoogle Scholar
  77. Kahn HA, Leibowitz HM, Ganley JP, et al. The Framingham eye study. II. Association of ophthalmic pathology with single variables previously measured in the Framingham Heart study. American Journal of Epidemiology 106: 33–41, 1977PubMedGoogle Scholar
  78. Kass MA. Timolol treatment prevents or delays glaucomatous visual field loss in individuals with ocular hypertension: a five-year, randomized, double-masked, clinical trial. Transactions of the American Ophthalmological Society 87: 598–618, 1989PubMedGoogle Scholar
  79. Kass MA, Gordon MO, Hoff MR, Parkinson JM, Kolker AE, et al. Topical timolol administration reduces the incidence of glaucomatous damage in ocular hypertensive individuals: a randomized, double-masked, long-term clinical trial. Archives of Ophthalmology 107: 1590–1598, 1989PubMedGoogle Scholar
  80. Katz IM, Berger ET. Efficacy and side effects of timolol and pilocarpine: a multicenter study. Glaucoma 3: 147–153, 1981Google Scholar
  81. Keates EU, Stone RA. Safety and effectiveness of concomitant administration of dipivefrin and timolol maleate. American Journal of Ophthalmology 91: 243–248, 1981PubMedGoogle Scholar
  82. Korey MS, Hodapp E, Kass MA, Goldberg I, Gordon M, et al. Timolol and epinephrine: long-term evaluation of concurrent administration. Archives of Ophthalmology 100: 742–745, 1982PubMedGoogle Scholar
  83. Krieglstein GK, Novack GD, Voepel E, Schwarzbach G, Lange U, et al. Levobunolol and metipranolol: comparative ocular hypotensive efficacy, safety, and comfort. British Journal of Ophthalmology 71: 250–253, 1987PubMedGoogle Scholar
  84. LeBlanc RP, Krip G. Timolol: Canadian multicenter study. Ophthalmology 88: 244–248, 1981Google Scholar
  85. Le Jeunne C, Munera Y, Hugues F-C. Systemic effects of three β-blocker eyedrops: Comparison in healthy volunteers of β1-and β2-adrenoreceptor inhibition. Clinical Pharmacology and Therapeutics 47: 578–583, 1990PubMedGoogle Scholar
  86. Lertora JJL, Mark AL, Johannsen UJ, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. A dose-related phenomenon. Journal of Clinical Investigation 56: 719–724, 1975PubMedGoogle Scholar
  87. Leske MC, Rosenthal J. Epidemiologic aspects of open-angle glaucoma. American Journal of Epidemiology 109: 250–272, 1979PubMedGoogle Scholar
  88. Levobunolol Study Group. Levobunolol: a beta-adrenoreceptor antagonist effective in the long-term treatment of glaucoma. (Appended). Ophthalmology 92: 1271–1276, 1985Google Scholar
  89. Levobunolol Study Group. Levobunolol: a four-year study of efficacy and safety in glaucoma treatment. Ophthalmology 96: 642–645, 1989Google Scholar
  90. Levy NS, Boone L. Betaxolol. Investigative Ophthalmology and Visual Science 23 (Suppl.): 92, 1982Google Scholar
  91. Levy NS, Boone L. Effect of 0.25% betaxolol vs placebo. Glaucoma 5: 230–232, 1983Google Scholar
  92. Levy NS, Boone L, Ellis E. A controlled comparison of betaxolol and timolol with long-term evaluation of safety and efficacy. Glaucoma 7: 54–62, 1985Google Scholar
  93. Lin L-L, Galin MA, Obstbaum SA, Katz I. Longterm timolol therapy. Survey of Ophthalmology 23: 377–380, 1979PubMedGoogle Scholar
  94. Liu G-S, Trope GE, Basu PK. A comparison of topical betoptic and timoptic on corneal re-epithelialization in rabbits. Journal of Toxicology — Cutaneous and Ocular Toxicology 6: 335–343, 1987Google Scholar
  95. Long D, Zimmerman T, Spaeth G, Novack G, Burke PJ, et al. Minimum concentration of levobunolol required to control intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. American Journal of Ophthalmology 99: 18–22, 1985PubMedGoogle Scholar
  96. Long DA, Johns GE, Mullen RS, Bowe RG, Alexander D, et al. Levobunolol and betaxolol: a double-masked controlled comparison of efficacy and safety in patients with elevated intraocular pressure. Ophthalmology 95: 735–741, 1988PubMedGoogle Scholar
  97. Lynch MG, Whitson JT, Brown RH, Nguyen H, Drake MM. Topical β-blocker therapy and central nervous system side effects: a preliminary study comparing betaxolol and timolol. Archives of Ophthalmology 106: 908–911, 1988PubMedGoogle Scholar
  98. Martin FJ. Timolol maleate: a report from the Glaucoma Clinic, Sydney Eye Hospital. Australian Journal of Ophthalmology 8: 177–178, 1980PubMedGoogle Scholar
  99. McMahon CD, Hetherington J, Hoskins HD, Shaffer RN. Timolol and pediatric glaucomas. Ophthalmology 88: 249–252, 1981PubMedGoogle Scholar
  100. McMahon CD, Shaffer RN, Hoskins HD, Hetherington J. Adverse effects experienced by patients taking timolol. American Journal of Ophthalmology 88: 736–738, 1979PubMedGoogle Scholar
  101. Mertè HI, Schnarr KD. Ophthalmic betaxolol: a twelve-week study in glaucoma patients. New Trends in Ophthalmology 2: 98–108, 1987Google Scholar
  102. Merte H-J, Stryz JR, Mertz M. Comparative studies of initial pressure reduction using metipranolol 0.3% and timolol 0.25% in eyes with open-angle glaucoma. Klinische Monatsblätter für Augenheilkunde 182: 286–289, 1983PubMedGoogle Scholar
  103. Mills KB, Wright G. A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study. British Journal of Ophthalmology 70: 39–42, 1986PubMedGoogle Scholar
  104. Mishima S. Ocular effects of beta-adrenergic agents. XII Jules Stein lecture. Survey of Ophthalmology 27: 187–208, 1982PubMedGoogle Scholar
  105. Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution. American Journal of Ophthalmology 102: 606–611, 1986PubMedGoogle Scholar
  106. Nelson WL, Kuritsky JN. Early postmarketing surveillance of betaxolol hydrochloride, September 1985-September 1986. American Journal of Ophthalmology 103: 592, 1987PubMedGoogle Scholar
  107. Neufeld AH. Experimental studies on the mechanism of action of timolol. Survey of Ophthalmology 23: 363–370, 1979PubMedGoogle Scholar
  108. Neufeld AH. Epinephrine and timolol: how do these drugs lower intraocular pressure? Annals of Ophthalmology 13: 1109–1111, 1981PubMedGoogle Scholar
  109. Novack GD. Ophthalmic beta-blockers since timolol. Survey of Ophthalmology 31: 307–327, 1987PubMedGoogle Scholar
  110. Ofner S, Smith TJ. Betaxolol in chronic obstructive pulmonary disease. Journal of Ocular Pharmacology 3: 171–176, 1987PubMedGoogle Scholar
  111. Ohno S, Ichiishi A, Matsuda H. Hypotensive effect of Carteolol on intraocular pressure elevation and secondary glaucoma associated with endogenous uveitis. Ophthalmologica 199: 41–45, 1989PubMedGoogle Scholar
  112. Öhrström A. Dose response of oral timolol combined with adrenaline. British Journal of Opthalmology 66: 242–246, 1982Google Scholar
  113. Öhrström A, Pandolfi M. Regulation of intraocular pressure and pupil size by β-blockers and epinephrine. Archives of Ophthalmology 98: 2182–2184, 1980PubMedGoogle Scholar
  114. Phillips CI. Timolol in operated closed-angle glaucoma. British Journal of Ophthalmology 64: 240–246, 1980PubMedGoogle Scholar
  115. Phillips CI, Gore SM, Gunn PM. Atenolol versus adrenaline eye drops and an evaluation of these two combined. British Journal of Ophthalmology 62: 296–301, 1978PubMedGoogle Scholar
  116. Phillips CI, Gore SM, Macdonald MJ, Cullen PM. Atenolol eye drops in glaucoma: a double-masked, controlled study. British Journal of Ophthalmology 61: 349–353, 1977PubMedGoogle Scholar
  117. Phillips CI, Howitt G, Rowlands DJ. Propranolol as ocular hypotensive agent. British Journal of Ophthalmology 51: 222–226, 1967PubMedGoogle Scholar
  118. Pillunat LE, Stodtmeister R. Pressure compliance test of the optic nerve head: influence of different antiglaucoma drugs (Summary). Survey of Ophthalmology 33 (Suppl.): 465–466, 1989PubMedGoogle Scholar
  119. Radius RL. Use of betaxolol in the reduction of elevated intraocular pressure. Archives of Opthalmology 101: 898–900, 1983Google Scholar
  120. Rakofsky SI, Melamed S, Cohen JS, Slight JR, Spaeth G, et al. A comparison of the ocular hypotensive efficacy of once-daily and twice-daily levobunolol treatment. Ophthalmology 96: 8–11, 1989PubMedGoogle Scholar
  121. Reiss GR, Brubaker RF. The mechanism of betaxolol, a new ocular hypotensive agent. Ophthalmology 90: 1369–1372, 1983PubMedGoogle Scholar
  122. Rolle BB, Franzone M. Effects of topical betaxolol on ocular hypertensive or glaucomatous eyes. New Trends in Ophthalmology 2: 87–94, 1987Google Scholar
  123. Savelsbergh-Fillette MP, Demailly P. Levobunolol compared with timolol for control of elevated intraocular pressure. French Journal of Opthalmology 11: 587–590, 1988Google Scholar
  124. Schlecht LP, Brubaker RF. The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology 95: 1212–1216, 1988PubMedGoogle Scholar
  125. Schmitz-Valckenberg P, Jonas J, Brambring DF. Reductions in pressure with metipranolol 0.1%. Zeitschrift für Praktische Augenheilkunde 5: 171–175, 1984Google Scholar
  126. Schnaudigel O-E, Becker H, Fuchs H-B. Carteolol: Practice-oriented testing of efficacy and tolerance of a new beta-blocker for glaucoma therapy. Klinische Monatsblätter für Augenheilkunde 192: 248–251, 1988PubMedGoogle Scholar
  127. Schoene RB, Abuan T, Ward RL, Beasley CH. Effects of topical betaxolol, timolol and placebo on pulmonary function in asthmatic bronchitis. American Journal of Ophthalmology 97: 86–92, 1984PubMedGoogle Scholar
  128. Schoene RB, Abaun T, Ward RL, Beasley CH. Reply. American Journal of Ophthalmology 100: 493–494, 1985Google Scholar
  129. Seamone C, LeBlanc R, Saheb N, Novack G. Efficacy of twice-daily levobunolol in the treatment of elevated intraocular pressure. Canadian Journal of Ophthalmology 23: 168–170, 1988PubMedGoogle Scholar
  130. Segal P, Skwierczyńska J. Mass screening of adults for glaucoma. Ophthalmologica 153: 336–348, 1967PubMedGoogle Scholar
  131. Serle JB, Lustgarten JS, Podos SM. A clinical trial of metipranolol, a noncardioselective beta-adrenergic antagonist, in ocular hypertension. American Journal of Ophthalmology 112: 302–307, 1991PubMedGoogle Scholar
  132. Silverstone D, Zimmerman T, Choplin N, Mundorf T, Rose A, et al. Evaluation of once-daily levobunolol 0.25% and timolol 0.25% therapy for increased intraocular pressure. American Journal of Ophthalmology 112: 56–60, 1991PubMedGoogle Scholar
  133. Smith JP, Weeks RH, Newland EF, Ward RL. Betaxolol and ace-tazolamide: combined ocular hypotensive effect. Archives of Ophthalmology 102: 1794–1795, 1984PubMedGoogle Scholar
  134. Smith RJ, Nagasubramanian S, Watkins R, Poinoosawmy D. Addition of timolol maleate to routine medical therapy: a clinical trial. British Journal of Ophthalmology 64: 779–781, 1980PubMedGoogle Scholar
  135. Smith RJH, Blamires T, Nagasubramanian S, Watkins R, Poinoosawmy D. Addition of pindolol to routine medical therapy: a clinical trial. British Journal of Ophthalmology 66: 102–108, 1982PubMedGoogle Scholar
  136. Smith SE, Smith SA, Reynolds F, Whitmarsh VB. Ocular and cardiovascular effects of local and systemic pindolol. British Journal of Ophthalmology 63: 63–66, 1979PubMedGoogle Scholar
  137. Soll DB. Evaluation of timolol in chronic open-angle glaucoma: once a day vs twice a day. Archives of Ophthalmology 98: 2178–2181, 1980PubMedGoogle Scholar
  138. Sommer A. Intraocular pressure and glaucoma. Editorial. American Journal of Ophthalmology 107: 186–188, 1989PubMedGoogle Scholar
  139. Sonntag JR, Brindley GO, Shields MB. Effect of timolol therapy on outflow facility. Investigative Ophthalmology and Visual Science 17: 293–296, 1978PubMedGoogle Scholar
  140. Sonty S, Schwartz B. The additive effect of timolol on open angle glaucoma patients on maximal medical therapy. Survey of Ophthalmology 23: 381–388, 1979PubMedGoogle Scholar
  141. Spiritus EM, Casciari R. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Correspondence. American Journal of Ophthalmology 100: 492–493, 1985PubMedGoogle Scholar
  142. Steinert RF, Thomas JV, Boger WP. Long-term drift and continued efficacy after multiyear timolol therapy. Archives of Ophthalmology 99: 100–103, 1981PubMedGoogle Scholar
  143. Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol: a six-month double-blind comparison. Archives of Ophthalmology 104: 46–48, 1986PubMedGoogle Scholar
  144. Stryz JR, Merté H-J. Comparison of different β-blockers in open angle glaucomas. In Greve et al. (Eds) Second European Glaucoma Symposium, Helsinki, 1984, pp. 119–123, Dr W. Junk Publishers, Dordrecht, 1985Google Scholar
  145. Thomas JV, Epstein DL. Timolol and epinephrine in primary open angle glaucoma: transient additive effect. Archives of Ophthalmology 99: 91–95, 1981PubMedGoogle Scholar
  146. Thorson JC. Concomitant glaucoma therapy with dipivefrin and timolol maleate. Transactions of the Ophthalmological Society of New Zealand 33: 24–26, 1981PubMedGoogle Scholar
  147. Trope GE, Liu G-S, Basu PK. Toxic effects of topically administered Betagan, Betoptic and Timoptic on regenerating corneal epithelium. Journal of Ocular Pharmacology 4: 359–366, 1988PubMedGoogle Scholar
  148. Vale J, Gibbs ACC, Phillips CI. Topical propranolol and ocular tension in the human. British Journal of Ophthalmology 56: 770–775, 1972PubMedGoogle Scholar
  149. Van Buskirk EM. Corneal anesthesia after timolol maleate therapy. American Journal of Ophthalmology 88: 739–743, 1979PubMedGoogle Scholar
  150. Van Buskirk EM. Adverse reactions from timolol administration. Ophthalmology 87: 447–450, 1980PubMedGoogle Scholar
  151. Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, et al. Betaxolol in patients with glaucoma and asthma. American Journal of Ophthalmology 101: 531–534, 1986PubMedGoogle Scholar
  152. Van Buskirk EM, Weinreb RN, Berry DP, Lustgarten JS, Podos SM, et al. Reply. American Journal of Ophthalmology 103: 600–601, 1987Google Scholar
  153. Viggósson G, Björnsson G, Ingvason JG. The prevalence of open-angle glaucoma in Iceland. Acta Ophthalmologica 64: 138–141, 1986PubMedGoogle Scholar
  154. Vukich JA, Leef DL, Allen RC. Betaxolol in patients with coexistant chronic open angle glaucoma and pulmonary disease. Investigative Ophthalmology and Visual Science 26 (Suppl.): 227, 1985Google Scholar
  155. Wandel T, Charap AD, Lewis RA, Partamian L, Cobb S, et al. Glaucoma treated with once-daily levobunolol. American Journal of Ophthalmology 101: 298–304, 1986PubMedGoogle Scholar
  156. Weinreb RN, Ritch R, Kushner FH. Effect of adding betaxolol to dipivefrin therapy. American Journal of Ophthalmology 101: 196–198, 1986PubMedGoogle Scholar
  157. Weinreb RN, Van Buskirk EM, Cherniack R, Drake MM. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. American Journal of Ophthalmology 106: 162–167, 1988PubMedGoogle Scholar
  158. Wettrell K, Wilke K, Pandolfi M. Topical atenolol versus pilocarpine: a double-blind study of the effect on ocular tension. British Journal of Ophthalmology 62: 292–295, 1978PubMedGoogle Scholar
  159. Williams T, Ginther WH. Hazards of ophthalmic timolol. Correspondence. New England Journal of Medicine 306: 1485–1486, 1982PubMedGoogle Scholar
  160. Worthen DM. Patient compliance and the ‘usefulness product’ of timolol. Survey of Ophthalmology 23: 403–406, 1979PubMedGoogle Scholar
  161. Zimmerman TJ, Boger WP. The beta-adrenergic blocking agents and the treatment of glaucoma. Survey of Ophthalmology 23: 347–362, 1979PubMedGoogle Scholar
  162. Zimmerman TJ, Harbin R, Pett M, Kaufman HE. Timolol and facility of outflow. Investigative Ophthalmology and Visual Science 16: 623–624, 1977PubMedGoogle Scholar

Copyright information

© Adis International Limited 1992

Authors and Affiliations

  • Anne M. V. Brooks
    • 1
  • W. E. Gillies
    • 1
  1. 1.Glaucoma Investigation and Research UnitThe Royal Victorian Eye and Ear HospitalEast MelbourneAustralia

Personalised recommendations